Endocrine emergencies are acute clinical conditions in which a rapid and significant alteration of one or more hormonal axes compromises hemodynamic, respiratory, neurological or metabolic stability. Severity does not depend only on the magnitude of the biochemical deviation, but also on the speed with which it develops and on the ability of compensatory systems to maintain homeostasis. In many situations, the precipitating event is not a “pure” endocrine problem, but an intercurrent factor such as sepsis, trauma, surgery, ischemia, abrupt discontinuation of chronic therapies, administration errors or drug interactions that exceed the organism’s adaptive reserve.
A distinctive feature of endocrine emergencies is their nature as a “network node”: glucocorticoid deficiency can precipitate shock and hypoglycemia, severe thyrotoxicosis can destabilize cardiovascular function and increase tissue oxygen consumption, a hypercalcemic crisis can alter consciousness and cardiac rhythm, and hyperosmolar dehydration can lead to thrombosis and multiorgan failure. Consequently, effective management requires two parallel actions: intensive support of vital functions and timely correction of the underlying endocrine mechanism, without waiting for complete confirmation when the clinical probability is high.
This page describes the general principles for recognizing and treating the main endocrine emergencies in adults, with a practical approach based on pathophysiology, therapeutic priorities and monitoring, with attention to the conditions that most frequently act as triggers.
In the initial phase, the priority is to identify whether the clinical picture is dominated by impairment of vital functions or by potentially rapidly reversible metabolic disturbances. Assessment follows an emergency logic: level of consciousness, ventilation and oxygenation, perfusion and blood pressure, temperature, blood glucose and signs of dehydration or fluid overload. At the same time, “endocrine” clues are sought, which are often clinically subtle: hyperpigmentation, weight loss, tachyarrhythmias, myxedema, signs of neuromuscular hypocalcemia, polyuria and polydipsia, history of glucocorticoid or antithyroid therapy, recent pituitary or thyroid surgery, chemotherapy, immunotherapy or drugs that interfere with endocrine function.
Essential diagnostic work-up must be organized so as not to delay lifesaving treatments. In many cases it is sufficient to draw samples before specific therapy when possible, but the absence of samples does not justify withholding urgent intervention. The most useful emergency profiles include electrolytes, renal function, osmolality and ketones when indicated, blood gas analysis, complete blood count and infectious markers, thyroid function when thyroid storm or myxedema is suspected, cortisol and adrenocorticotropic hormone when adrenal insufficiency is likely, and calcium, phosphorus and magnesium in tetany and hypercalcemic crisis. Imaging is targeted: brain computed tomography and pituitary magnetic resonance imaging if apoplexy is suspected, abdominal computed tomography or targeted imaging if a catecholaminergic crisis occurs in the context of known pheochromocytoma, and ultrasound or computed tomography if abdominal complications and infectious triggers are plausible.
A cross-cutting principle is the management of therapeutic timing. Some emergencies are “pharmacologically sequential”, meaning that the order of administration affects both efficacy and safety. In thyroid storm, for example, blocking hormone synthesis and then inhibiting release with iodine is more rational than reversing the order. In myxedema coma, administration of thyroid hormones can increase glucocorticoid requirements and makes steroid coverage prudent until concomitant insufficiency has been excluded. In severe hypocalcemia, magnesium correction may be essential to make calcium correction effective.
Adrenal crisis is a potentially fatal condition due to insufficient glucocorticoid availability, often associated with mineralocorticoid deficiency in primary forms. It may occur in patients with known insufficiency who do not adjust therapy during intercurrent illness, as the first manifestation of undiagnosed insufficiency, or as a consequence of abrupt discontinuation or rapid reduction of exogenous glucocorticoids with suppression of the hypothalamic-pituitary-adrenal axis. The pathophysiology combines reduced vasopressor response to catecholamines, altered vascular permeability, reduced gluconeogenesis and impaired ability to maintain vascular tone, with risk of refractory shock and hypoglycemia. In primary forms, aldosterone loss promotes hypovolemia, hyponatremia and hyperkalemia.
Clinically, suspicion arises in the presence of unexplained hypotension or shock, nausea, vomiting, abdominal pain, severe asthenia, fever, confusion, hypoglycemia, hyponatremia and often hyperkalemia. The absence of hyperkalemia does not exclude the crisis, especially in secondary or tertiary forms. Since progression can be rapid, management must be immediate and centered on three pillars: restoration of perfusion with isotonic crystalloids, correction of hypoglycemia when present, and administration of stress-dose hydrocortisone. When possible, cortisol and adrenocorticotropic hormone are sampled before treatment, but hydrocortisone administration must not be delayed if the clinical picture is severe.
Recommended acute treatment consists of intravenous hydrocortisone with an initial 100 mg bolus followed by 200 mg over the next 24 hours, preferably as a continuous infusion or as regular divided doses. In parallel, rapid volume expansion with normal saline is initiated, adjusted according to blood pressure, urine output and cardiopulmonary status; in cases with hypoglycemia, glucose is added as needed. Clinically relevant hyperkalemia requires management according to standard protocols, but often improves with fluids and steroids. Identification and treatment of the trigger, particularly infection or surgery, are integral parts of resolving the crisis. After stabilization, the approach evolves toward identifying the cause, defining the chronic regimen and educating the patient on prevention, including the availability of sick day plans and tools for recognizing risk.
Thyroid storm is the most severe expression of thyrotoxicosis, characterized by a marked increase in the action of thyroid hormones on the heart, central nervous system, muscle and metabolism. It does not necessarily correspond to higher hormone levels than those seen in uncomplicated thyrotoxicosis, because severity depends on adrenergic overstimulation, the inflammatory response and the presence of precipitants such as infections, surgery, trauma, discontinuation of antithyroid drugs, iodine load, childbirth or acute cardiovascular events. The main risk is rapid hemodynamic destabilization with tachyarrhythmias, heart failure, hyperthermia, neurological disturbances and multiorgan failure.
Recognition is clinical and must be rapid. Hyperthermia, agitation or delirium up to coma, diarrhea and vomiting, jaundice, marked tachycardia, atrial fibrillation, signs of heart failure and hypotension are typical. Since overlap with sepsis or other hyperinflammatory syndromes is possible, the use of clinical scoring systems may support suspicion, but does not replace clinical judgment when instability is evident. Management must take place in a monitored setting, with support of vital functions, temperature control with physical measures and aggressive treatment of the trigger.
Specific treatment is based on a pathophysiological sequence: reducing peripheral effects with beta-blockers, blocking hormone synthesis with thionamides, inhibiting release with iodine after adequate pretreatment, reducing peripheral conversion and supporting the axis with glucocorticoids, and considering additional therapies when necessary. One commonly used strategy consists of propranolol to control tachycardia and adrenergic symptoms, propylthiouracil with a loading dose followed by frequent administrations or high-dose methimazole, subsequent administration of inorganic iodine after synthesis has been blocked, and stress-dose hydrocortisone. The choice of beta-blocker and its titration must take heart failure and bronchospasm into account; in patients with severe heart failure, more cautious management and intensive cardiology collaboration may be necessary. Cholestyramine may be considered as an adjuvant to increase thyroid hormone clearance in selected cases. In refractory cases or when contraindications exist, extracorporeal removal procedures may be considered in expert centers, but the foundation remains trigger control and sequential therapy.
Myxedema coma represents the most severe form of hypothyroidism, often occurring in patients with long-standing untreated or undertreated hypothyroidism and precipitating when infections, cold exposure, sedatives, trauma or surgery exceed compensatory mechanisms. Many patients are not actually comatose, but present along a continuum of neurological deterioration. The pathophysiology includes hypoventilation with hypercapnia, reduced thermogenesis with hypothermia, bradycardia and reduced contractility with possible shock, water retention with hyponatremia, and a general metabolic slowing that increases sensitivity to central nervous system depressant drugs.
Clinical suspicion is based on altered mental status, hypothermia, bradycardia, hypotension, hypoventilation, dry and cold skin, myxedema and signs of water retention. Tests typically show a profile of severe hypothyroidism, but the diagnosis is clinical because waiting for results can be dangerous. Management takes place in an intensive care unit or equivalent setting, with ventilatory support when necessary and cautious correction of electrolyte disturbances and blood glucose. Rewarming must be cautious, favoring passive measures to reduce the risk of peripheral vasodilation and hemodynamic collapse in already compromised patients.
Hormonal therapy consists of intravenous levothyroxine with a loading dose followed by a maintenance dose; some protocols use a loading dose in the range of several hundred micrograms, adjusted for age and cardiovascular risk, with possible addition of liothyronine in selected non-responding cases and with close monitoring, given the arrhythmic risk. A crucial step is stress-dose glucocorticoid coverage until concomitant adrenal insufficiency has been reasonably excluded, because the introduction of thyroid hormones can increase glucocorticoid metabolism and precipitate a crisis in vulnerable subjects. In parallel, infections and other triggers are treated, and complications such as hyponatremia, hypoglycemia and heart failure are managed. Improvement is often gradual and requires close monitoring of ventilation, rhythm and perfusion, as well as dose reassessment as the patient recovers.
Acute hyperglycemic crises include diabetic ketoacidosis and hyperosmolar hyperglycemic state, conditions that share hyperglycemia and dehydration, but differ because ketosis and acidosis predominate in the former, while hyperosmolality predominates in the latter. Mixed forms exist in clinical practice. The common mechanism is relative or absolute insulin deficiency with increased counterregulatory hormones, which promote gluconeogenesis, glycogenolysis, lipolysis and ketone body production. Dehydration and electrolyte disturbances, particularly involving potassium, are key determinants of severity and of the risk of arrhythmias and renal failure.
Suspicion arises from polyuria, polydipsia, nausea, vomiting, abdominal pain, Kussmaul breathing and altered mental status, with dehydration and signs of hypoperfusion. Essential diagnostics integrate blood glucose, ketones, blood gas analysis for pH and bicarbonate, electrolytes with calculation of the anion gap, renal function and osmolality, together with the search for a trigger such as infection, myocardial infarction, stroke, insulin discontinuation or drugs. Since therapeutic decisions depend on potassium and osmolality, serial monitoring is part of the therapy itself.
Treatment is based on restoration of volume status, intravenous insulin as a fixed-rate infusion and potassium management. Modern recommendations emphasize starting an intravenous insulin infusion at 0.1 units per kg per hour in most cases of ketoacidosis and mixed forms, with adjustments based on response, potassium and blood glucose. In hyperosmolar states without significant ketosis, lower rates are often used, since the initial priority is correction of dehydration and hyperosmolality, avoiding rapid osmolar changes that increase the risk of neurological complications. Potassium replacement is critical: insulin and correction of acidosis shift potassium into the intracellular compartment and may precipitate hypokalemia, so insulin must be adjusted if potassium is low and electrolyte correction must precede or accompany insulin therapy. Transition to subcutaneous insulin requires temporal overlap to prevent metabolic rebound and should occur when acidosis and the anion gap have resolved and oral intake is possible. Identification of the trigger and prevention of recurrence through education and review of the insulin regimen are integral parts of care.
Severe hypoglycemia is an emergency because the brain depends on glucose and neuroglycopenia can rapidly progress to seizures, coma and neurological injury. In diabetology, the most common cause is an imbalance between insulin or secretagogue therapy and glucose intake or use, often favored by renal failure, reduced food intake, uncompensated physical activity or alcohol consumption. However, in the emergency department, hypoglycemia always requires etiological reasoning because it may signal sepsis, adrenal insufficiency, hepatic failure, malignancies, pituitary insufficiency or, rarely, non-iatrogenic hyperinsulinism.
Urgent treatment is guided by whether the patient can take carbohydrates orally. When the patient cannot protect the airway or is unconscious, correction must be parenteral with intravenous glucose or glucagon, depending on the availability of venous access and the clinical context. The response must be verified with serial checks, because many causes, especially long-acting drugs or organ dysfunction, lead to recurrence. In patients treated with sulfonylureas or other secretagogues, recurrence is particularly insidious and may require prolonged observation and strategies to prevent reappearance.
After stabilization, the emergency is completed by analysis of the context and by a plan to prevent new episodes. This includes review of antidiabetic therapy, assessment of renal and hepatic function, recognition of patterns of hypoglycemia unawareness and, when indicated, use of glucose monitoring technologies. Management cannot be reduced to “correction and discharge”, because severe hypoglycemia is an indicator of vulnerability and predicts future events if the underlying determinants are not addressed.
Hypercalcemic crisis is an acute condition in which increased serum calcium causes dehydration, neurological disturbances, gastrointestinal symptoms and arrhythmic risk, up to renal failure and coma. In adults, the main causes are hyperparathyroidism and malignancy-associated hypercalcemia, but in an emergency setting the priority is to recognize severity and start correction that rapidly lowers calcium and interrupts the vicious cycle of osmotic diuresis and renal impairment. Symptoms are proportional not only to the absolute value, but also to the rapidity of onset and the presence of cardiac and renal comorbidities.
Initial treatment is based on rehydration with normal saline, which increases glomerular filtration and promotes calciuresis. In severe or symptomatic cases, modern guidelines for malignant hypercalcemia support the use of drugs that reduce bone resorption and calcemia: calcitonin for a more rapid but transient effect, and intravenous bisphosphonates or denosumab for more sustained control, with the choice guided by renal function and oncological context. Treatment of the cause, particularly control of neoplastic disease or management of hyperparathyroidism, is essential to prevent recurrence. In selected situations, especially with severe renal failure or refractoriness, dialysis may be considered as a rescue option.
Hypercalcemic crisis requires close monitoring of mental status, cardiac rhythm, urine output, electrolytes and renal function. The objective is to reduce calcium effectively while avoiding rapid imbalances in volume and sodium, especially in older patients or those with heart disease. Once the acute phase has been overcome, clarifying the etiology with parathyroid hormone, vitamin D and malignancy markers is crucial, because the subsequent pathway changes radically between hyperparathyroidism and malignant hypercalcemia.
Severe acute hypocalcemia is a neuromuscular and cardiological emergency because it can cause tetany, laryngospasm, seizures and QT prolongation with arrhythmic risk. Causes include post-surgical hypoparathyroidism, hypomagnesemia, acute pancreatitis, sepsis, tumor lysis, renal failure and drugs. The clinical picture includes perioral and acral paresthesias, cramps, Chvostek and Trousseau signs, bronchospasm, neuromuscular irritability and, in the most severe cases, altered consciousness and arrhythmias.
Urgent treatment consists of intravenous calcium administration, typically as calcium gluconate, with electrocardiographic monitoring, followed by continuous infusion or repeated dosing according to response. Practical recommendations describe an initial bolus of 10% calcium gluconate diluted in a volume and infused slowly, repeatable until symptom control, followed by an infusion titrated according to calcemia and clinical status. Correction of magnesium is essential when hypomagnesemia is present, because magnesium deficiency can make calcium correction refractory and impair both secretion and action of parathyroid hormone.
Management also includes identification of the cause and transition to oral therapy with calcium and active forms of vitamin D when indicated, especially in hypoparathyroidism. In the postoperative thyroid or parathyroid setting, early surveillance and timely treatment reduce the risk of respiratory and neurological complications. In this scenario as well, the emergency does not end with numerical normalization, but with clinical stabilization and definition of a maintenance and monitoring plan.
Pituitary apoplexy is an acute syndrome due to hemorrhage or infarction of a pituitary adenoma or, more rarely, of the normal gland. It is a neuroendocrine emergency because it combines neurological risk from compression of the optic chiasm and cranial nerves with metabolic and hemodynamic risk from acute corticotropic insufficiency. The typical picture includes sudden and severe headache, vomiting, visual deficits, ophthalmoplegia, altered mental status and, in severe cases, hemodynamic collapse.
Initial management requires stabilization of vital functions, urgent neurological and ophthalmological evaluation and correction of possible adrenal insufficiency. Guidelines indicate that in hemodynamically unstable patients, empirical steroid therapy with intravenous hydrocortisone is appropriate as an initial bolus followed by infusion or repeated doses, after samples have been collected for an essential endocrine profile when possible. Imaging, preferably pituitary magnetic resonance imaging, is central to confirming the diagnosis and evaluating compression. The decision between conservative management and surgical decompression depends on the severity of visual and neurological deficits, clinical evolution and radiological characteristics.
After the acute phase, a complete endocrine assessment is necessary because multiple pituitary deficits are frequent and may require chronic replacement therapies, with particular attention to the cortico-adrenal and thyroid axes. Follow-up also includes management of the underlying adenoma and surveillance for recurrence or residual growth.
Catecholaminergic crisis associated with pheochromocytoma or paraganglioma is a cardiovascular emergency characterized by severe and labile hypertension, arrhythmias, myocardial ischemia, pulmonary edema, shock and multiorgan dysfunction. It may be precipitated by surgery, drugs, anesthesia, tumor manipulation or intercurrent events. The pathophysiology derives from excess catecholamines, which increase vasoconstriction, heart rate and cardiac contractility, and can induce stress cardiomyopathy and coronary vasospasm.
Recognition requires clinical suspicion in the presence of paroxysmal hypertensive crises, headache, sweating, palpitations, pallor and hyperglycemia, especially if the patient has a history of a known tumor or elevated metanephrines. In the acute phase, management is dominated by control of blood pressure and perfusion in an intensive care setting. A fundamental principle is to avoid isolated beta-blockade in the presence of uncontrolled catecholamine excess, because it may cause unopposed alpha-mediated vasoconstriction and worsening of the crisis. The rational strategy involves alpha-adrenergic control first and only subsequently, if necessary, beta control for tachyarrhythmias, always in a monitored setting.
Catecholaminergic crisis is often a prelude to the need for definitive tumor treatment, but surgery requires preoperative stabilization with alpha-blockade, volume expansion and anesthesiological planning. The pathway must be coordinated with endocrinology, anesthesia and surgery in experienced centers, because perioperative management is an integral part of reducing mortality and complication risk.
Sodium disorders are among the most frequent and dangerous manifestations of endocrine emergencies, because they reflect an alteration in water balance and osmotic tone with neurological consequences. Hyponatremia may result from adrenal insufficiency, severe hypothyroidism, syndrome of inappropriate antidiuretic hormone secretion and mixed conditions; hypernatremia may occur in central or nephrogenic diabetes insipidus, especially when access to water is limited. The greatest risk is cerebral dysfunction from cellular edema or dehydration and, on the therapeutic side, the risk of osmotic demyelination or cerebral edema due to overly rapid correction.
The emergency approach must distinguish clinical severity, the probable duration of the disturbance and volume status. In forms with severe neurological symptoms, initial correction aims to improve symptoms rapidly, but with controlled increases in serum sodium and close monitoring. When adrenal insufficiency is suspected, hyponatremia is often part of a systemic picture and may improve only after steroid therapy and volume correction. In diabetes insipidus, hypernatremia is the result of free water loss and requires calculated water replacement and, in central forms, use of desmopressin with close monitoring to avoid treatment-induced hyponatremia.
In all cases, the sodium emergency is not simply “correcting a number”, but recognizing the underlying mechanism and establishing a strategy that reduces the neurological risk both of the disturbance and of its correction. Optimal management integrates intensive care measures, guideline-based correction criteria and an etiological diagnosis that includes endocrine evaluation when clinical clues suggest it.